PB
$49.46
+1.54
(+3.21%)
As of Oct 22, 2026, 9:34 PM EDT · cached
Price history
Prestige Consumer Healthcare Inc (PBH) is trading up at $49.46 (+3.21%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Prestige Consumer Healthcare Inc revenue & net income history (FY2017–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2017Mar 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $882.1M | $1.04B | $975.8M | $963.0M | $943.4M | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B |
| Growth (year over year) | +9.4% | +18.0% | −6.3% | −1.3% | −2.0% | +15.2% | +3.8% | −0.2% | +1.1% | −4.3% |
| Gross profit | $500.3M | $576.5M | $555.6M | $552.2M | $547.5M | $620.6M | $625.3M | $624.4M | $634.5M | $595.6M |
| Gross margin | 56.7% | 55.4% | 56.9% | 57.3% | 58.0% | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating income | $205.6M | $215.5M | $67.5M | $291.2M | $297.4M | $329.9M | −$22.4M | $342.4M | $336.8M | $309.4M |
| Operating margin | 23.3% | 20.7% | 6.9% | 30.2% | 31.5% | 30.4% | −2.0% | 30.4% | 29.6% | 28.4% |
| Net income | $69.4M | $339.6M | −$35.8M | $142.3M | $164.7M | $205.4M | −$82.3M | $209.3M | $214.6M | $190.3M |
| Net margin | 7.9% | 32.6% | −3.7% | 14.8% | 17.5% | 18.9% | −7.3% | 18.6% | 18.9% | 17.5% |
| EPS (diluted) | $1.30 | $6.34 | −$0.69 | $2.78 | $3.25 | $4.04 | −$1.65 | $4.17 | $4.29 | $3.91 |
| Balance sheet | ||||||||||
| Cash and equivalents | $41.9M | $32.5M | $27.5M | $94.8M | $32.3M | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M |
| Total assets | $3.91B | $3.76B | $3.44B | $3.51B | $3.43B | $3.67B | $3.35B | $3.32B | $3.40B | $3.49B |
| Total liabilities | $3.09B | $2.58B | $2.35B | $2.34B | $2.07B | $2.09B | $1.91B | $1.66B | $1.57B | $1.61B |
| Long-term debt | $2.19B | $1.99B | $1.80B | $1.73B | $1.48B | $1.48B | $1.35B | $1.14B | $992.4M | $994.0M |
| Shareholders' equity | $822.5M | $1.18B | $1.10B | $1.17B | $1.36B | $1.58B | $1.45B | $1.66B | $1.83B | $1.89B |
| Cash flow | ||||||||||
| Operating cash flow | $148.7M | $210.1M | $189.3M | $217.1M | $235.6M | $259.9M | $229.7M | $248.9M | $251.5M | $257.6M |
| Capital expenditure | $2.98M | $12.5M | $10.5M | $14.6M | $22.2M | $9.64M | $7.78M | $9.55M | $8.22M | $11.2M |
| Free cash flow | $145.7M | $197.6M | $178.8M | $202.6M | $213.4M | $250.3M | $221.9M | $239.4M | $243.3M | $246.4M |
| Share buybacks | $0 | $0 | $50.0M | $56.7M | $11.9M | $0 | $50.0M | $25.0M | $51.5M | $156.3M |
RevenueNet incomeNet margin (right axis, %)
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $283.8M | $290.3M | $296.5M | $249.5M | $274.1M | $283.4M | $281.6M | $265.7M |
| Growth (year over year) | −0.9% | +2.7% | +7.0% | −6.6% | −3.4% | −2.4% | −5.0% | +6.5% |
| Gross profit | $157.4M | $161.0M | $170.0M | $140.3M | $151.6M | $157.4M | $146.3M | $136.2M |
| Gross margin | 55.5% | 55.5% | 57.3% | 56.2% | 55.3% | 55.5% | 51.9% | 51.3% |
| Operating income | $84.3M | $92.0M | $88.4M | $71.8M | $79.7M | $82.5M | $75.5M | $52.5M |
| Operating margin | 29.7% | 31.7% | 29.8% | 28.8% | 29.1% | 29.1% | 26.8% | 19.8% |
| Net income | $54.4M | $61.0M | $50.1M | $47.5M | $42.2M | $46.7M | $53.9M | $29.2M |
| Net margin | 19.2% | 21.0% | 16.9% | 19.0% | 15.4% | 16.5% | 19.1% | 11.0% |
| EPS (diluted) | $1.09 | $1.22 | $1.00 | $0.95 | $0.86 | $0.97 | $1.13 | $0.61 |
| Balance sheet | ||||||||
| Cash and equivalents | $51.5M | $50.9M | $97.9M | $139.5M | $119.1M | $62.4M | $63.9M | $89.1M |
| Total assets | $3.32B | $3.33B | $3.40B | $3.43B | $3.44B | $3.49B | $3.49B | $4.57B |
| Total liabilities | $1.59B | $1.54B | $1.57B | $1.58B | $1.62B | $1.67B | $1.61B | $2.65B |
| Long-term debt | $1.06B | $1.00B | $992.4M | $992.7M | $993.1M | $1.03B | $994.0M | $2.01B |
| Shareholders' equity | $1.73B | $1.79B | $1.83B | $1.86B | $1.82B | $1.83B | $1.89B | $1.92B |
| Cash flow | ||||||||
| Operating cash flow | $69.8M | $65.1M | $61.8M | $79.0M | $57.5M | $78.3M | $42.8M | $70.8M |
| Capital expenditure | $2.03M | $1.57M | $3.48M | $838.0K | $2.10M | $3.03M | $5.21M | $3.70M |
| Free cash flow | $67.8M | $63.5M | $58.4M | $78.2M | $55.4M | $75.3M | $37.6M | $67.1M |
| Share buybacks | $11.8M | $2.40M | $11.3M | $34.8M | $75.0M | $45.8M | $690.0K | $0 |
From Prestige Consumer Healthcare Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Prestige Consumer Healthcare Inc
- Headquarters
- Tarrytown, New York From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International